Test of isunakinra alone or with pembrolizumab for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (isunakinra plus pembrolizumab) for people with a specific type of colorectal cancer (MSS, RAS-mutated) that has a high tumor mutational burden. It may help if other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer (MSS type) with a RAS mutation and a tumor mutational burden (TMB) of 10 or higher.
- Your cancer must be measurable on scans and have gotten worse after at least one prior treatment for advanced disease.
- You need to be fairly active and able to care for yourself (ECOG 0 or 1).
- Your kidney, liver, and blood counts need to be within certain normal limits.
- You must not be pregnant or breastfeeding, and you must use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing three different combinations of existing and new drugs for advanced or metastatic colorectal cancer that hasn't improved with standard treatments or has spread to the liver. The goal is to see which combination works best and is safe for patients like you.
This trial tests a combination of radiation therapy with three drugs (an immunotherapy, a chemotherapy pill, and a targeted therapy) for advanced colorectal cancer. It aims to see if this combination can shrink tumors and improve outcomes for people whose cancer has not responded to standard treatments.
This trial tests a combination of immunotherapy drugs for people with a specific type of colorectal cancer (MSS, or microsatellite stable) that has stopped responding to standard chemotherapy. The goal is to see if this new treatment can shrink tumors or slow the cancer's growth.
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
This trial tests a combination of two extra drugs (pirfenidone and sintilimab) added to standard chemotherapy before surgery. The goal is to see if this combination can help shrink or control colorectal cancer that has spread to the lining of the abdomen.
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.